Asset Details
Do you wish to reserve the book?
Clinical score based on CGRP, PD-1, and PD-L1 for PICC-related bloodstream infections in breast cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical score based on CGRP, PD-1, and PD-L1 for PICC-related bloodstream infections in breast cancer
Do you wish to request the book?
Clinical score based on CGRP, PD-1, and PD-L1 for PICC-related bloodstream infections in breast cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical score based on CGRP, PD-1, and PD-L1 for PICC-related bloodstream infections in breast cancer
2025
Overview
Peripherally inserted central catheter (PICC)-related bloodstream infections (BSIs) are serious complications in breast cancer patients. Reliable early risk assessment remains limited. Female breast cancer patients (n = 384) receiving PICCs were retrospectively analyzed. Serum CGRP levels were measured by ELISA, while PD-1 and PD-L1 expression was quantified via qPCR. A 3-point BioScore was calculated by assigning one point per abnormal biomarker (CGRP < 42.817 pg/mL, PD-1 > 2.301, PD-L1 < 1.613). Patients were stratified into low (0), intermediate (1–2), or high (3) risk groups. The cohort was split into training (n = 269) and validation (n = 115) sets. BSIs occurred in 78 patients (20.3%). The BioScore demonstrated excellent discrimination (AUC 0.96 in training and 0.93 in validation) and good calibration (Hosmer–Lemeshow
P
= 0.797 and 0.875). BSI rates rose with BioScore category. While the BioScore was derived from biomarker values measured at the time of clinical suspicion for BSI, its strong discriminatory performance suggests potential for earlier application, such as at routine follow-ups, pending prospective validation. The BioScore demonstrated excellent internal discrimination and calibration in a retrospective, single-center cohort. Further external and prospective validation is necessary before clinical use.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/499
/ Adult
/ Aged
/ BioScore
/ Breast Neoplasms - complications
/ Calcitonin gene-related peptide
/ Calcitonin Gene-Related Peptide - blood
/ Catheter-Related Infections - blood
/ Catheter-Related Infections - diagnosis
/ Catheter-Related Infections - etiology
/ Catheterization, Peripheral - adverse effects
/ CGRP
/ Female
/ Fever
/ Humanities and Social Sciences
/ Humans
/ Patients
/ PD-1
/ PD-L1
/ PICC-related bloodstream infection
/ Programmed Cell Death 1 Receptor - blood
/ Science
/ Training
